FDA is alerting clinical laboratory staff and health care providers that it is monitoring the impact of viral mutations, including the variant from the United Kingdom, the B.1.1.7 variant, on authorized SARS-CoV-2 molecular tests, and that false negative results can occur with any molecular test.
Read more: FDA Issues Alert Regarding SARS-CoV-2 Viral Mutation to Health Care Providers and Clinical Laboratory Staff